MA29273B1 - Combinaison synergique de xolair/omalizumab/e25 et d'un agent immunosuppresseur - Google Patents

Combinaison synergique de xolair/omalizumab/e25 et d'un agent immunosuppresseur

Info

Publication number
MA29273B1
MA29273B1 MA30171A MA30171A MA29273B1 MA 29273 B1 MA29273 B1 MA 29273B1 MA 30171 A MA30171 A MA 30171A MA 30171 A MA30171 A MA 30171A MA 29273 B1 MA29273 B1 MA 29273B1
Authority
MA
Morocco
Prior art keywords
immunosuppresseur
xolair
omalizumab
agent
synergistic combination
Prior art date
Application number
MA30171A
Other languages
English (en)
Inventor
Charles Edward Owen
Howard George Fox
Christoph Walker
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA29273B1 publication Critical patent/MA29273B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39566—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against immunoglobulins, e.g. anti-idiotypic antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Transplantation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'INVENTION CONCERNE UNE COMPOSITION PHARMACEUTIQUE COMPRENANT UN ANTICORPS ANTI-IGE, ET AU MOINS UN AGENT IMMUNOSUPPRESSEUR ADDITIONNEL, DANS LAQUELLE LES INGRÉDIENTS ACTIFS SONT PRÉSENTÉS DANS CHAQUE CAS SOUS FORME LIBRE OU SOUS FORME D'UN SEL PHARMACEUTIQUEMENT ACCEPTABLE, ET ÉVENTUELLEMENT AU MOINS UN EXCIPIENT PHARMACEUTIQUEMENT ACCEPTABLE, ET SONT DESTINÉS À ÊTRE ADMINISTRÉ SIMULTANÉMENT, SÉPARÉMENT, OU SUCCESSIVEMENT.
MA30171A 2005-02-04 2007-08-28 Combinaison synergique de xolair/omalizumab/e25 et d'un agent immunosuppresseur MA29273B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0502358.5A GB0502358D0 (en) 2005-02-04 2005-02-04 Organic compounds

Publications (1)

Publication Number Publication Date
MA29273B1 true MA29273B1 (fr) 2008-02-01

Family

ID=34355808

Family Applications (1)

Application Number Title Priority Date Filing Date
MA30171A MA29273B1 (fr) 2005-02-04 2007-08-28 Combinaison synergique de xolair/omalizumab/e25 et d'un agent immunosuppresseur

Country Status (20)

Country Link
US (1) US20080206237A1 (fr)
EP (1) EP1846031A1 (fr)
JP (1) JP2008528650A (fr)
KR (1) KR20070100344A (fr)
CN (1) CN101111265A (fr)
AR (1) AR053541A1 (fr)
AU (1) AU2006210098A1 (fr)
BR (1) BRPI0607349A2 (fr)
CA (1) CA2595976A1 (fr)
GB (1) GB0502358D0 (fr)
GT (1) GT200600023A (fr)
IL (1) IL184713A0 (fr)
MA (1) MA29273B1 (fr)
MX (1) MX2007009436A (fr)
NO (1) NO20074497L (fr)
PE (1) PE20061203A1 (fr)
RU (1) RU2007132980A (fr)
TN (1) TNSN07304A1 (fr)
TW (1) TW200640487A (fr)
WO (1) WO2006082052A1 (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1850865A2 (fr) * 2005-02-08 2007-11-07 Novartis AG Induction d'un anticorps antilymphocyte
DK2708559T3 (en) 2008-04-11 2018-06-14 Chugai Pharmaceutical Co Ltd Antigen-binding molecule capable of repeatedly binding two or more antigen molecules
ES2708842T3 (es) * 2008-09-17 2019-04-11 Xencor Inc Composiciones y métodos para para tratar trastornos mediados por IgE
KR20120102125A (ko) * 2009-12-18 2012-09-17 사노피 Ｇｐｖｉ에 대한 신규한 길항제 항체 및 그의 ｆａｂ 단편 및 그의 용도
JP6030452B2 (ja) 2010-11-30 2016-11-24 中外製薬株式会社 複数分子の抗原に繰り返し結合する抗原結合分子
CN103492565B (zh) 2011-02-25 2021-01-29 中外制药株式会社 FcγRIIb特异性Fc抗体
AR085749A1 (es) * 2011-04-01 2013-10-23 Novartis Ag Formulaciones
EP3939996A1 (fr) 2011-09-30 2022-01-19 Chugai Seiyaku Kabushiki Kaisha Molécule se liant à l'antigène favorisant la disparition des antigènes ayant une pluralité d'activités biologiques
TW201809008A (zh) 2014-12-19 2018-03-16 日商中外製藥股份有限公司 抗ｃ５抗體及使用方法
US10000560B2 (en) 2014-12-19 2018-06-19 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies, polypeptides containing variant Fc regions, and methods of use
CN114773470A (zh) 2015-02-05 2022-07-22 中外制药株式会社 包含离子浓度依赖性的抗原结合结构域的抗体，fc区变体，il-8-结合抗体及其应用
KR20180095740A (ko) 2015-02-27 2018-08-27 추가이 세이야쿠 가부시키가이샤 Il-6 관련 질환 치료용 조성물
US10947320B2 (en) 2015-12-18 2021-03-16 University Of Notre Dame Du Lac Covalent heterobivalent antibody inhibitors and ligands
WO2017110981A1 (fr) 2015-12-25 2017-06-29 Chugai Seiyaku Kabushiki Kaisha Anticorps anti-myostatine et procédés d'utilisation
GB201610198D0 (en) 2016-06-10 2016-07-27 Ucb Biopharma Sprl Anti-ige antibodies
CA3026050A1 (fr) 2016-08-05 2018-02-08 Chugai Seiyaku Kabushiki Kaisha Composition pour la prophylaxie ou le traitement de maladies liees a il-8
JP7191833B2 (ja) 2017-01-30 2022-12-19 中外製薬株式会社 抗スクレロスチン抗体およびその使用
JOP20190271A1 (ar) 2017-05-24 2019-11-21 Novartis Ag بروتينات مطعّمة بسيتوكين- الجسم المضاد وطرق الاستخدام للاضطرابات المتعلقة بالمناعة
DE102017215154A1 (de) 2017-08-30 2019-02-28 Markus Bläss Zusammensetzung zur topischen Behandlung von nicht-Mikroorganismus-verursachten entzündlichen Haut- und Schleimhauterkrankungen
US12030959B1 (en) 2023-07-05 2024-07-09 Genentech, Inc. Anti-IgE antibody therapy for multiple food allergies

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6172213B1 (en) * 1997-07-02 2001-01-09 Genentech, Inc. Anti-IgE antibodies and method of improving polypeptides
US5994511A (en) * 1997-07-02 1999-11-30 Genentech, Inc. Anti-IgE antibodies and methods of improving polypeptides
GB0200429D0 (en) * 2002-01-09 2002-02-27 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
CN101111265A (zh) 2008-01-23
TW200640487A (en) 2006-12-01
AU2006210098A1 (en) 2006-08-10
KR20070100344A (ko) 2007-10-10
GB0502358D0 (en) 2005-03-16
JP2008528650A (ja) 2008-07-31
TNSN07304A1 (en) 2008-12-31
NO20074497L (no) 2007-10-26
PE20061203A1 (es) 2006-12-19
AR053541A1 (es) 2007-05-09
IL184713A0 (en) 2007-12-03
CA2595976A1 (fr) 2006-08-10
RU2007132980A (ru) 2009-03-10
BRPI0607349A2 (pt) 2009-09-01
GT200600023A (es) 2006-08-16
MX2007009436A (es) 2007-08-17
EP1846031A1 (fr) 2007-10-24
WO2006082052A1 (fr) 2006-08-10
US20080206237A1 (en) 2008-08-28

Similar Documents

Publication Publication Date Title
MA29273B1 (fr) Combinaison synergique de xolair/omalizumab/e25 et d'un agent immunosuppresseur
MA29744B1 (fr) Formulations posologiques solides de medicaments presentant une adsorption buccale amelioree
NO2014016I2 (no) Dimetylfumarat
HK1080364A1 (en) Oral pharmaceutical forms of liquid drugs having improved bioavailability
CY1114594T1 (el) Χρηση της [d-meala]3[etval]4-κυκλοσπορινης για την θεραπεια μολυνσης απο ηπατιτιδα c και φαρμακευτικη συνθεση που περιλαμβανει την εν λογω [d-meala]3[etval]4-κυκλοσπορινη
WO2002042462A3 (fr) Agents therapeutiques et methodes d'utilisation de ces agents therapeutiques pour traiter une maladie amyloidogenique
BRPI0418270A (pt) métodos de tratamento e de controle, de tratamento ou prevenção, de controle de um distúrbio do sistema nervoso central, e para reduzir ou evitar um efeito adverso, e, composição farmacêutica
MXPA04000920A (es) Derivados de aminoisoxazol activos como inhibidores de la cinasa.
EA200401009A1 (ru) Предварительно желатинированный крахмал в композиции с контролируемым высвобождением
NO20040547L (no) Amino-ftalazinonderivater aktive som kinaseinhibitorer, fremgangsmate for deres fremstilling og farmasoytiske sammensetninger inneholdende disse.
WO2005094374A3 (fr) Composes inhibiteurs de cftr contenant des hydrazides et utilisations de ceux-ci
WO2002028999A3 (fr) Profils d'expression genique dans les cellules granulocytaires
HK1080459A1 (en) Novel pyrimidineamide derivatives and the use thereof
BR0210122A (pt) Composto ou um sal farmaceuticamente aceitável do mesmo, método para o tratamento ou prevenção de uma doença, uso do composto ou de seu sal, e, método para preparar o mesmo
MA29675B1 (fr) Nouvelle formulation pharmaceutique contenant un biguanide et un derive de thiazolidinedione
BRPI0414721A (pt) formulações estabilizadas de fosfatidilserina
DK1383752T3 (da) Deutererede 3-piperidinopropiophenoner samt lægemidler indeholdende disse forbindelser
BRPI0410049A (pt) composto ou um sal ou estereoisÈmero farmaceuticamente aceitável do mesmo, uso de um composto, composição farmacêutica, e, kit farmacêutico
EE200100104A (et) 5-HT4 agonisti või antagonisti uus peroraalne ravimvorm
MXPA03010054A (es) Composiciones que comprenden lopinavir y metodos para aumentar la biodisponibilidad de agentes farmaceuticos.
WO2005044186A3 (fr) Formulations pharmaceutiques destinees a etre inhalees utilisant des agents dessechants et methodes d'administration desdites formulations pharmaceutiques
SE9902935D0 (sv) Pharmaceutical compositions
EA200702386A1 (ru) Твердая фармацевтическая композиция для продолжительного высвобождения 1-(2,3,4-триметоксибензил)пиперазина и способ ее получения
BR0011845A (pt) Complexo farmacêutico
BR0313175A (pt) Formulações farmacêuticas compreendendo combinações de epinastina, pseudoefedrina e metilefedrina